Reuters -- Swiss drugmaker Roche Holding AG (ROG.VX) said its ocrelizumab had met its primary endpoint in a late-stage trial for seropositive rheumatoid arthritis, but said safety issues remained. Roche said patients showed an improvement in signs and symptoms of the disease at week 24 and at week 48 in a Phase III trial when taking ocrelizumab compared with a placebo.
